α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells by Redondo-Muñoz, Javier et al.
NEOPLASIA
41 integrin and 190-kDa CD44v constitute a cell surface docking complex for
gelatinase B/MMP-9 in chronic leukemic but not in normal B cells
Javier Redondo-Mun˜oz,1 Estefanı´a Ugarte-Berzal,1 Jose´ A. Garcı´a-Marco,2 Mercedes Herna´ndez del Cerro,1
Philippe E. Van den Steen,3 Ghislain Opdenakker,3 Marı´a Jose´ Terol,4 and Angeles Garcı´a-Pardo1
1Departamento de Fisiopatologı´a Celular y Molecular, Centro de Investigaciones Biolo´gicas, Consejo Superior de Investigaciones Cientı´ficas, Madrid, Spain;
2Servicio de Hematologı´a, Hospital Puerta de Hierro, Madrid, Spain; 3Rega Institute for Medical Research, University of Leuven, Leuven, Belgium; and 4Servicio
de Hematologı´a y Medicina Oncolo´gica, Hospital Clı´nico, Valencia, Spain
As B-cell chronic lymphocytic leukemia
(B-CLL) progresses, malignant cells ex-
travasate and infiltrate lymphoid tis-
sues. Several molecules, including gela-
tinase B/MMP-9, contribute to these
processes. Although mainly a secreted
protease, some MMP-9 is present at the
B-CLL cell surface and the function,
mode of anchoring, and interactions of
this MMP-9 are unknown. Here we show
that anti–MMP-9 antibodies immunopre-
cipitated a 190-kDa CD44v isoform and
41 integrin from B-CLL cells, but not
from normal B cells. Function-blocking
antibodies to 41 or CD44, or transfec-
tion with specific siRNAs, decreased
cell-associated proMMP-9 and increased
the secreted form. B-CLL cells attached
to and bound proMMP-9 and active
MMP-9, and this was inhibited by block-
ing the expression or function of 41
or CD44. The MMP-9 hemopexin domain
was critical in these interactions. 41
and 190-kDa CD44v (but not CD44H)
formed a complex at the cell surface,
since they both coimmunoprecipitated
with anti-4, anti-1, or anti-CD44 anti-
bodies. Immunofluorescence analyses
confirmed that 41 and CD44v colocal-
ized with MMP-9. Binding of proMMP-9
inhibited B-CLL cell migration, and
this required MMP-9 proteolytic ac-
tivity. Thus, we have identified 41 and
CD44v as a novel proMMP-9 cell surface
docking complex and show that cell-
associated MMP-9 may regulate B-CLL
cell migration and arrest. (Blood. 2008;
112:169-178)
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by
the accumulation of CD5 B lymphocytes in the peripheral
blood.1,2 As the disease progresses, these cells infiltrate the bone
marrow and secondary lymphoid tissue, resulting in poor progno-
sis.1,2 Several molecules that participate in B-CLL cell migration
and invasion have been identified. These include the CCL21,
CCL19, and CXCL12 chemokines,3,4 the vascular endothelial
growth factor (VEGF),5 and the L2 and 41 integrins.5,6
Other molecules known to play a role in cell migration are
matrix metalloproteinases (MMPs).7-9 B-CLL cells produce and
secrete progelatinase-B/proMMP-9 (92 kDa),10 and elevated
intracellular levels of this MMP correlate with advanced stage
and poor patient survival.11 We and others have shown that
MMP-9 plays an important role in B-CLL transendothelial
migration and invasion through basement membranes.6,11 We
also recently showed that the constitutive levels of proMMP-9
in B-CLL cells are significantly higher than in normal B cells,
and that secretion of proMMP-9 by B-CLL cells is up-regulated
by 41 integrin, CXCR4, or CCR7 (the receptors for CXCL
12 and CCL19/CCL21, respectively) engagement.6,12 Besides
up-regulating proMMP-9 levels, 41 integrin ligation also
induces the formation of podosomes in B-CLL cells and
the localization of proteolytically active MMP-9 to these
invasive structures.6
Although mainly present as a secreted soluble form,
proMMP-9 has also been detected at the B-CLL cell surface by
flow cytometry and cell biotinylation analyses.11 Indeed, we
recently showed that MMP-9 is present at the B-CLL cell
membrane fraction in apparently both the proform and the active
form.6 Since MMP-9 does not have a transmembrane region, its
association to the cell surface requires binding to cell membrane
proteins.13 In other cell types, these proteins include CD44
(murine carcinoma and human melanoma cells),14,15 L2 and
M2 integrins (neutrophils),16 the 2 chain of collagen IV
(breast epithelial cells),17 and the membrane form of the DNA
repair protein Ku (monocytic cells).18 Targeting MMP-9 to the
cell surface is thought to localize and enhance its proteolytic
activity at the pericellular space, and this has been demonstrated
upon MMP-9 binding to CD44.15,19 In contrast, MMP-9 interac-
tion with RECK (reversion-inducing-cysteine-rich protein with
Kazal motifs) apparently inhibits the enzyme,20 and binding to
LRP (low-density lipoprotein receptor-related protein) leads to
MMP-9 internalization.21 These previous findings indicate that
localization of MMP-9 at the cell surface is complex and
appears to regulate multiple aspects of this enzyme.13
The function and molecular associations of MMP-9 at the
B-CLL cell surface are not known. These are important issues to be
clarified since MMP-9 may play a crucial role in the progression of
B-CLL. In the present study, we show that MMP-9 (the pro and
active forms) specifically binds 41 integrin and a high-molecular-
weight variant of CD44 at the B-CLL cell surface. These 2 proteins
thus constitute a novel membrane docking complex for MMP-9 in
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malignant cells. Moreover, we show that cell-bound MMP-9 may
regulate B-CLL cell migration and arrest.
Methods
Patients and cells
Peripheral blood samples were collected after informed consent was
obtained in accordance with the Declaration of Helsinki from 8 B-CLL
patients (Table 1) and 2 mantle-cell lymphoma patients. CD5 B lympho-
cytes were purified by Ficoll-Hypaque (Nycomed, Oslo, Norway) centrifu-
gation and negative selection with anti–CD3-conjugated Dynabeads (Dynal
Biotech ASA, Oslo, Norway). The resulting B-cell population was more
than 95% CD19 and more than 90% CD5 ( 70% CD5 for mantle
B cells), as determined by flow cytometry (Document S1, available on the
Blood website; see the Supplemental Materials link at the top of the online
article). Tonsillar B lymphocytes were obtained from 2 adult individuals
undergoing routine tonsillectomy and purified to more than 95% CD19
and more than 75% CD5 with anti-CD19– and anti-CD5–conjugated
Dynabeads. B lymphocytes from 3 healthy donors (PB-BLs) were purified
from buffy coat cells by Ficoll-Hypaque centrifugation and anti-CD19–
conjugated Dynabeads, resulting in more than 92% CD19 cells. The
Epstein-Barr virus (EBV)–transformed HUT112 and BRO168 B-cell lines,
established from normal B lymphocytes, have been previously reported.6
Human umbilical vein endothelial cells (HUVECs) were cultured as
reported.6
Approval was obtained from the Consejo Superior de Investigaciones
Cientı´ficas Bioethics Review Board for these studies. Additional materials
and methods are available in Document S1.
Results
41 Integrin and a high-molecular-weight CD44 isoform
coimmunoprecipitate with proMMP-9 in B-CLL cells
We recently showed that 41 integrin regulates proMMP-9
secretion and localization in podosomes in B-CLL cells.6 A fraction
of the secreted proMMP-9 may bind to the cell surface as MMP-9
is consistently detected at the B-CLL cell membrane.6,11 We
therefore investigated whether 41 integrin could interact with
surface-associated MMP-9. B-CLL cells from 3 different patients
were cultured for 24 hours and lysed, and lysates incubated with an
anti–MMP-9 pAb bound to protein A–Sepharose. The presence of
MMP-9 in the immunoprecipitates was confirmed by gelatin
zymography. This analysis showed a major 92-kDa band, corre-
sponding to proMMP-9 and a minor band of 120 kDa, likely
representing the proMMP-9/lipocalin complex previously de-
scribed in B-CLL cells11 (shown in Figure 1A for 2 representative
patients). Further analysis of these immunoprecipitates by Western
blotting revealed the presence of 2 bands of 140 kDa and 120 kDa,
which corresponded to the 4 and 1 integrin subunits, respec-
tively (Figure 1B). Identical results were obtained for patient 3 (not
shown). The 4 (Figure 1B) or 1 (not shown) bands were not
present in control immunoprecipitates in which rabbit IgG was
incubated with the cell lysates. Although B-CLL cells also express
L2 integrin and, in some cases, 31, these integrins did not
coimmunoprecipitate with proMMP-9 (results not shown).
Figure 1. proMMP-9 interacts with 41 integrin and a high-molecular-weight CD44 isoform in B-CLL cells. Lysates from 2  107 B-CLL cells cultured for 24 hours in
RPMI/0.1% FCS were immunoprecipitated with anti–MMP-9 pAbs or with rabbit IgG (Ctl), and analyzed by gelatin zymography (A) and Western blotting (B). The results from
2 patients of the 3 analyzed with identical results are shown. (C) Lysates from 2  107 B-CLL cells transfected with MMP-9 or control siRNA were immunoprecipitated with
anti–MMP-9 pAbs and analyzed by Western blotting. The efficiency of the siRNA transfection was confirmed by gelatin zymography. (D) B-CLL cell lysates were
immunoprecipitated with the indicated Abs and analyzed by gelatin zymography. Anti-HLA and anti–MMP-9 Abs were used as negative and positive controls, respectively.
(E) Gelatin zymographic analysis of the cell fractions and conditioned media of the indicated B-cell types, after 24-hour cell culture.
Table 1. Clinical characteristics of B-CLL patients
Patient Sex/age, y Stage* CD38/ZAP-70† Ig status
1 M/59 B/II / ND
2 M/65 B/II / ND
3 F/84 A/I / ND
4 F/69 B/II / ND
5 M/62 B/II / ND
6 M/80 A/0 / Mutated
7 M/62 A/0 / Mutated
8 M/78 A/0 / Unmutated
No patient received therapy.
ND indicates not determined.
*According to Binet et al22 and Rai et al23 criteria.
†The coexpression of CD38 and ZAP-70 is now determined routinely in all B-CLL
samples as this analysis apparently has prognostic value.24,25
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Because CD44 is known to bind MMP-9 in several cell
types,14,15,19 we also analyzed the presence of CD44 in the
proMMP-9 immunoprecipitates of B-CLL cells. As shown in
Figure 1B, the anti-CD44 Ab recognized a single band of 190 kDa,
probably corresponding to a high-molecular-weight CD44 isoform
(known as CD44v), while the standard 85/95-kDa CD44 (known as
CD44H) was not detected (Figure 1B). Another membrane protein,
CD45, was also absent in these immunoprecipitates (Figure 1B),
confirming the specificity of the coimmunoprecipitation of
proMMP-9 with 41 and 190-kDa CD44v. Identical results were
obtained when proMMP-9 was immunoprecipitated from lysates of
freshly isolated cells, which had not been in culture for 24 hours
(Figure S1).
To further establish the specificity of the anti–MMP-9 Ab, we
analyzed the lysates of B-CLL cells that had been transfected with
either MMP-9 siRNA or a control siRNA. The anti–MMP-9 Ab did
not immunoprecipitate the 4 or 1 integrin subunits or 190-kDa
CD44v from MMP-9 siRNA–transfected cells, while these proteins
were clearly visible in proMMP-9 immunoprecipitates from con-
trol siRNA–transfected cells (Figure 1C). Gelatin zymographic
analysis confirmed that the MMP-9 siRNA reduced the amount of
membrane-bound and secreted proMMP-9 by 3-fold, compared
with untransfected or control siRNA–transfected cells (shown in
Figure 1C for membrane-bound proMMP-9).
To then determine whether Abs to 41 integrin or CD44
pulled down proMMP-9, B-CLL cell lysates were incubated with
specific Abs to 4, 1, or CD44, and the immunoprecipitates
analyzed by gelatin zymography. As shown in Figure 1D, all 3 Abs
pulled down proMMP-9, while anti-HLA Abs did not. The amount
of proMMP-9 in these immunoprecipitates was similar to that
pulled down by anti–MMP-9 Abs, used as positive control
(Figure 1D).
To establish if the observed presence and interactions of
surface-bound proMMP-9 also occurred in non–B-CLL B cells,
normal peripheral blood B lymphocytes, BRO168 and HUT112
cells, CD5 tonsillar B cells, and CD5 mantle lymphoma B cells
were cultured for 24 hours. The membrane and cytosolic fractions
were then separated and analyzed by gelatin zymography. Figure
1E shows that proMMP-9 was clearly present in the conditioned
media of these cells, but absent in their cellular fractions.
Blocking 41 or CD44 function with antibodies or peptides
significantly reduces the levels of B-CLL cell
surface–associated proMMP-9
To determine whether 41 and 190-kDa CD44v serve as surface
receptors for proMMP-9, we first studied the effect of blocking
41 function on cell surface–bound proMMP-9. Equal numbers
of cells from 3 different patients were incubated with either the
HP2/1 mAb or the CS1 peptide, 2 well-known inhibitors of 41
function26-28; after 24 hours, the membrane and cytosolic cellular
fractions were separated and analyzed by gelatin zymography. In
agreement with our previous results,6 no proMMP-9 was detected
in the cytosolic fraction (not shown). The levels of membrane-
associated proMMP-9 were significantly reduced (P  .01) after
cell incubation with HP2/1 or CS1 (Figure S2A left panel). In
contrast, the HP1/7 mAb, which does not block 41 function26 or
the control peptide CS3,27,28 had no effect (Figure S2A).
To determine whether the reduced expression of membrane-
bound proMMP-9 correlated with increased secreted levels of this
MMP, we analyzed the conditioned media of the same 3 samples by
gelatin zymography. As shown in Figure S2A (right panel), cell
treatment with HP2/1 or CS1 significantly increased (P  .05) the
amount of secreted proMMP-9, while incubation with HP1/7 or
CS3 had no effect.
We next performed similar experiments to study the effect of
blocking CD44 function on the amount of surface-bound and
secreted proMMP-9. As shown in Figure S2B, incubation of
B-CLL cells (2 patients) with anti-CD44 mAb significantly reduced
(P .05) membrane-associated proMMP-9 and increased (P .05)
secreted proMMP-9. The control anti-HLA mAb had no effect
(Figure S2B). None of the inhibitors of 41 or CD44 function
affected the levels of MMP-9 mRNA, as confirmed by reverse
transcription–polymerase chain reaction (RT-PCR; not shown).
These results indicated that both 41 integrin and CD44 were
important for maintaining proMMP-9 at the B-CLL cell membrane.
Knocking down the expression of the 1 integrin subunit or
CD44 in B-CLL cells significantly reduces the amount of
surface-bound proMMP-9 and increases the levels of secreted
proMMP-9
To confirm the results obtained by blocking the function of 41 or
CD44, we transfected B-CLL cells (3 patients) with 2 different
siRNAs for the 1 integrin subunit, since 41 is the major
integrin in these cells,29,30 or for CD44, or with a control siRNA.
siRNA transfection had a minor effect on B-CLL cell viability
(shown in Figure S3 for 2 representative samples). Western blotting
analyses confirmed that both 1 siRNAs significantly reduced
(average 52% and 57% reduction, P  .05, for siRNA1 and
siRNA2, respectively, with similar results for all 3 samples) the
total levels of 1, with respect to untransfected or control
siRNA–transfected cells (Figure S4A). Likewise, both CD44
siRNAs significantly reduced (average 60%, P  .01, and 67%
reduction, P  .001, for siRNA1 and siRNA2, respectively) the
levels of CD44H, while 190-kDa CD44v was no longer detectable
(Figure S4B).
Surface expression of the 1 and 4 integrin subunits was also
effectively reduced by both 1 siRNAs (shown in Figure 2A for 1
siRNA2 and for 2 representative samples). This siRNA reduced the
MFI average values from 7.8 to 2.2, and from 22.6 to 3.8, for the 1
and 4 subunits, respectively, representing a 71% and 80%
reduction on the surface expression of these subunits. The control
siRNA had no effect (Figure 2A). All 3 samples analyzed gave
similar results. The levels of CD44 on 1 siRNA–transfected cells
did not change (Figure 2A), indicating that siRNA transfection did
not affect the expression of other membrane proteins. Concomitant
with the blockage of 41 surface expression, zymographic
analyses revealed that proMMP-9 levels were significantly reduced
by both 1 siRNA1 and siRNA2 (P  .05 and P  .01, respec-
tively) in the cell membrane fraction, while they were not affected
by the control siRNA (Figure 2B). In contrast, and as previously
observed by inhibiting 41 function, the levels of secreted
proMMP-9 were significantly increased (P  .05) on 1 siRNA–
transfected cells (Figure 2B).
CD44 surface expression was also effectively blocked after
CD44 siRNA2 (or siRNA1, not shown) transfection, with average
MFI values reduced from 19.2 to 2.1, or 91% reduction, while the
control siRNA had no effect (Figure 2C). The surface expression of
the 4 or 1 integrin subunits was not affected by transfection with
CD44 siRNAs (Figure 2C). Zymographic analysis of the cell
membrane fraction showed that both CD44 siRNAs, but not the
control siRNA, significantly (P  .01) reduced the amount of
surface-bound proMMP-9 (Figure 2D). This reduction correlated
with a significant (P  .05) increase of secreted proMMP-9
(Figure 2D).
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To confirm these results, we studied whether surface-bound
proMMP-9 levels were restored upon longer B-CLL cell culture,
thus allowing for 41 and CD44 re-expression. Figure S5A shows
that proMMP-9 levels were nearly fully recovered after 72 hours,
in correlation with the surface re-expression of 41 and CD44
(Figure S5B).
B-CLL cells bind soluble proMMP-9 and attach to immobilized
proMMP-9 via 41 and CD44; normal B cells do not bind or
adhere to proMMP-9
The preceding results indicated that both 41 integrin and
190-kDa CD44v coimmunoprecipitated with proMMP-9 and were
necessary to localize proMMP-9 at the B-CLL cell surface. To
further establish that a direct interaction existed between these
2 proteins and proMMP-9, we analyzed the binding of soluble
proMMP-9 to B-CLL cells by flow cytometry. These analyses
revealed that the constitutive surface expression of proMMP-9
increased 2.4-fold (average of 3 patients with similar results) upon
incubating the cells with soluble proMMP-9 (Figure 3A). This
indicated that soluble proMMP-9 could bind to the B-CLL cell
surface. To determine whether 41 integrin and/or CD44 were
involved in this binding, we incubated the cells with the HP2/1
mAb, the CS1 peptide, or an anti-CD44 Ab, prior to adding
proMMP-9. Inhibiting the function of 41 or CD44 significantly
(P  .05) reduced the expression of surface-bound proMMP-9 to
constitutive levels, while the control HP1/7 mAb or the inactive
CS3 peptide had no effect (Figure 3A).
To confirm the above results, we performed similar binding
experiments using B-CLL cells transfected with control, 1, or
CD44 siRNAs. Figure 3B shows, for a representative patient, that
gene silencing of any of these 2 proteins blocked soluble proMMP-9
binding to B-CLL cells, while the control siRNA had no effect. All
3 patients studied gave identical results, with average MFI values
significantly decreasing (P  .05) from 3.4 (untransfected or
control siRNA–transfected cells) to basal levels (1.3). As a control
for the integrity of the membrane after these transfections, HLA
expression was similar for all 3 siRNA conditions (Figure 3B) and
for untransfected cells (not shown). These results established that
both 41 integrin and CD44 are required for soluble proMMP-9
binding to B-CLL cells. Further analyses of these interactions
revealed that proMMP-9 remained bound to the cell surface for the
24 hours of the assay (Figure S6A), that binding was saturable
(Figure S6B), and that it did not result in internalization of the
41/CD44/proMMP-9 complex (Figure S6C).
We then determined if non–B-CLL cells could also bind soluble
proMMP-9. In agreement with the immunoprecipitation experi-
ments shown in Figure 1E, BRO168 cells did not express
membrane proMMP-9 constitutively (Figure 3C), despite their
high expression of 41 integrin (not shown). Moreover, BRO168
cells (or PB-BLs, not shown) were unable to bind soluble
proMMP-9, even after activation of the integrin with Mn2 (Figure
3C). In contrast, Mn2-treated BRO168 cells efficiently bound
soluble VCAM-1, and this binding was inhibited by the CS1
peptide (Figure 3C), indicating that 41 was fully functional in
these cells.
We next studied whether proMMP-9 could serve as an anchor-
ing point for B-CLL cells and whether 41 and CD44 mediated
this adhesion. B-CLL cells from 3 different patients attached to
immobilized proMMP-9 (Figure 3D), and the percentage of
adhesion (30%) was similar to that of cells attached to VCAM-1
(33%). Each individual sample gave similar results. Blocking the
function of 41 integrin with HP2/1 or CS1, abolished cell
adhesion to proMMP-9 (and to VCAM-1, not shown). In contrast,
the control HP1/7 mAb or the CS3 peptide had no effect. Likewise,
cell incubation with the anti-CD44 mAb diminished cell adhesion
to proMMP-9 by 53% (Figure 3D). Moreover, knocking down the
expression of 41 or CD44 by specific siRNA transfection
significantly (P  .01) reduced cell adhesion to proMMP-9 to the
basal levels of adhesion to BSA (Figure 3D). In contrast, transfec-
tion with a control siRNA had no effect (Figure 3D). These results
clearly indicated that proMMP-9 supported adhesion of B-CLL
cells and that both 41 integrin and CD44 were required for this
adhesion. Interestingly, this dual requirement appeared to be
unique for adhesion to proMMP-9, since B-CLL cell adhesion to
VCAM-1 was completely blocked by transfection with 1 siRNA,
but was not affected by transfection with CD44 siRNA (Figure 3D).
To determine whether non–B-CLL B cells attached to
immobilized proMMP-9, BRO168 and HUT112 cells, PB-BLs,
Figure 2. Effect of 1 integrin subunit or CD44 gene
silencing on B-CLL cell membrane-bound and se-
creted proMMP-9. (A) B-CLL cells were transfected with
control or 1 siRNA and analyzed by flow cytometry.
Shaded areas represent 1 siRNA-cells; dotted lines,
control siRNA cells; and continuous lines, untransfected
cells. Representative results from 2 samples of the
3 studied are shown. (B) Gelatin zymographic analysis of
proMMP-9 on the membrane fraction and the conditioned
media of untransfected or siRNA-transfected B-CLL cells.
11 and 12 indicate the 2 different 1 siRNAs used. Ctl
indicates control siRNA. Values represent the average of
the 3 samples after normalizing the proMMP-9 levels of
untransfected cells to 100. (C) Flow cytometric analysis
of B-CLL cells (shown for 2 samples) transfected with
control or CD44 siRNA. Line codes are as in panel A.
(D) Gelatin zymography of proMMP-9 on the membrane
fraction and the conditioned media of untransfected or
siRNA-transfected B-CLL cells. CD441 and CD442 indi-
cate the 2 different CD44 siRNAs used. Values represent
the average of all 3 patients after normalizing proMMP-9
levels in untransfected cells to 100. *P  .05; **P  .01.
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and CD5 tonsillar or mantle lymphoma B cells were used. All
these cells attached well to VCAM-1 (Figure 3E), and adhesion
was completely inhibited by HP2/1 or CS1 (not shown). In
contrast, these cells did not attach to proMMP-9, and this was
particularly striking for HUT112 cells, where adhesion to
VCAM-1 was nearly 90% (Figure 3E). Altogether, these results
suggested that the ability to use 41 and CD44 as receptors for
immobilized or soluble proMMP-9 was a unique characteristic
of B-CLL cells.
Further characterization of MMP-9 interaction with B-CLL cells
To determine which region of proMMP-9 was important for its
interaction with B-CLL cells, we used recombinant proteins31
representing the full-length proMMP-9 (rproMMP-9fl) or several
truncated forms (Figure 4A). B-CLL cells attached to and bound
rproMMP-9fl efficiently (Figure 4B,C), and this was inhibited by
the HP2/1 and anti-CD44 Abs (83% and 69% inhibition, respec-
tively), but not by the HP1/7 Ab (not shown). Removal of the
hemopexin domain (rproMMP-9Hem) or the hemopexin and
O-glycosylated (OG) domains (rproMMP-9HemOG) signifi-
cantly reduced (P  .001) the ability to support B-CLL cell
adhesion (Figure 4B) and the binding to the cell surface (P  .01)
(Figure 4C) in all 4 patients studied. Removal of the OG domain
alone had a minor although significant effect on cell adhesion
(P  .01) and soluble binding (P  .05). Mutating the catalytic E
residue (rproMMP-9mutE) did not affect the proMMP-9 cell
binding property (Figure 4B,C). These results indicated that
proMMP-9 interaction with the B-CLL cell surface involves the
hemopexin domain and some contribution of the OG domain.
To further extend the physiological relevance of proMMP-9
interaction with B-CLL cells, we studied whether mature/active
MMP-9 retained this ability. Treatment of proMMP-9 with APMA
completely converted the proform into the reported 83/62-kDa
MMP-9 active forms8,9 (Figure 4D). These active forms mediated
cell adhesion and bound to B-CLL cells as efficiently as proMMP-9
(Figure 4E,F). Both events were significantly inhibited in all
3 samples studied by blocking 41 or CD44 with specific Abs or
peptides (Figure 4E,F).
The CD44v isoform present in B-CLL cells
coimmunoprecipitates with the 4 or 1 integrin subunits
and is absent in normal or non-CLL B cells
Since both CD44 and 41 integrin appeared to be receptors for
proMMP-9, we studied whether these 2 proteins interacted at the
B-CLL surface. Fresh B-CLL cells (2 patients) were lysed and
lysates immunoprecipitated with either anti-4 or anti-1
mAbs, followed by protein G–bound secondary Abs. Western
Figure 3. 41 integrin and CD44 mediate soluble proMMP-9 binding to B-CLL cells and adhesion of these cells to immobilized proMMP-9. (A) B-CLL cells, with or
without previous incubation with the indicated Abs or peptides, were incubated for 30 minutes with or without proMMP-9 (10 g/mL) and analyzed by flow cytometry using
anti–MMP-9 pAbs. Const MMP-9 indicates constitutive MMP-9. (B) Identical binding experiments were performed with B-CLL cells transfected with the indicated siRNAs. HLA
expression was also analyzed as a control for membrane integrity. A representative sample of the 3 studied with identical results is shown. (C) BRO168 cells were incubated
with proMMP-9 or VCAM-1 and analyzed by flow cytometry. The binding of VCAM-1 was also measured after cell preincubation with the CS1 peptide. (D) BCECF-AM-labeled
B-CLL cells (5  105; 3 patients), with or without previous incubation with the indicated Abs or peptides, or transfected with the indicated siRNAs, were added to wells coated
with 10 g/mL proMMP-9 or VCAM-1. After 90 minutes at 37°C, attached cells were quantitated using a fluorescence analyzer. Average values, each with duplicate
determinations, represent the percentage of the total number of cells added. (E) The indicated BCECF-AM–labeled B cells were added to proMMP-9– or VCAM-1–coated wells
and attached cells measured as explained. All determinations were done in triplicate and values represent the average of 3 (BRO168, HUT112, PBL-BL) or 2 (tonsillar and
mantle lymphoma BL) independent experiments. Bar codes are as in panel D. *P  .05; **P  .01.
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blotting analysis of these immunoprecipitates revealed the
presence of 190-kDa CD44v and the absence of 95-kDa CD44H
(Figure 5A). Moreover, the anti-CD44 mAb immunoprecipi-
tated the 4 and 1 integrin subunits (Figure S7). These results
suggested that the CD44v/41 complex was responsible for
the binding of proMMP-9 to the B-CLL cell surface. Because
normal or mantle lymphoma B cells did not bind proMMP-9,
albeit expressing fully functional 41, we analyzed the
presence of the CD44v isoform on these cells by Western
blotting. Figure 5B shows that while the membrane fraction of
B-CLL cells contained both the CD44H and CD44v isoforms, all
other B cells analyzed contained only CD44H. Further character-
ization of the CD44v present on the B-CLL samples, with
specific Abs to some of the variable exons, indicated that it
Figure 4. Further characterization of MMP-9 interaction with B-CLL cells. (A) Schematic domain structure of the recombinant full-length (fl) and proMMP-9 variants used
(modified from 31). Pro indicates prodomain; Act, active site; FN, gelatin-binding fibronectin-like domain; Zn2, Zn2-binding domain; OG, O-glycosylated domain, with vertical
lines indicating probable attachment sites for O-linked sugars; and Hem, hemopexin domain. A indicates that the catalytic Glu/E402 residue was substituted by alanine.
(B) BCECF-AM–labeled B-CLL cells were added to wells coated with the indicated rproMMP-9 variants (110 nM each) and cell adhesion was measured as explained.
(C) Binding of soluble rproMMP-9 variants to B-CLL cells, measured by flow cytometry. Values in panels B and C represent the average data from cells of the 4 patients studied.
(D) proMMP-9 was treated with 2 mM APMA for 4 hours at 37°C and activation confirmed by gelatin zymography. (E) BCECF-AM–labeled B-CLL cells were added to wells
coated with proMMP-9 or active MMP-9 (110 nM each), and cell adhesion was measured as explained. (F) Flow cytometric analysis of the binding of soluble proMMP-9 or
active MMP-9 to B-CLL cells. Values in panels E and F represent the averages obtained with cells of 3 patients studied. MFI indicates mean fluorescence intensity. *P  .05;
**P  .01; ***P  .001.
Figure 5. Characterization of CD44 isoforms on CLL
and non-CLL B cells. (A) Lysates from 2  107 B-CLL
cells that had been in RPMI/0.1% FCS for 24 hours were
immunoprecipitated with the indicated Abs (control: anti-
HLA) and analyzed by Western blotting. (B) The mem-
brane fraction from the same B-CLL samples shown in
panel A and from the indicated B cells was analyzed by
Western blotting using anti-CD44 Abs. The presence of
the 190-kDa CD44v isoform on B-CLL cells is indicated.
A vertical line has been inserted to indicate a composition
of 2 different gels. (C) The cell lysate from a representa-
tive B-CLL sample was immunoprecipitated with anti–
MMP-9 Abs and analyzed by Western blotting using Abs
specific for CD44 variable exons. Lysates from BLM cells
were used as control for the anti-v6 mAb. (D) B-CLL cells
were incubated with or without proMMP-9 in the presence
or absence of the indicated Abs, and binding was ana-
lyzed by flow cytometry. Average values are shown.
Const MMP-9 indicates constitutive MMP-9. *P  .05.
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contained v3, v4,5, v7,8, and v10 (shown in Figure 5C for a
representative sample). In agreement with a recent report,32 v6
was absent, and we established the functionality of the anti-v6
Ab on BLM melanoma cells (Figure 5C). These results were
confirmed by fluorescence-activated cell sorting (FACS) analy-
sis of the B-CLL and normal B cells (Figure S8). Moreover, the
Abs against the CD44 variable exons blocked the binding of
soluble proMMP-9 to B-CLL cells in the 3 patients studied
(shown in Figure 5D for anti-v7,8 and anti-v10 Abs), confirming
the functional implication of these variable exons in the binding
of CD44v to proMMP-9.
MMP-9 colocalizes with 41 integrin and CD44v at the B-CLL
cell surface, and both receptors are required for MMP-9 cell
surface anchoring
The preceding results indicated that CD44v interacted with 41
and that both proteins served as surface docking receptors for
proMMP-9. To confirm that CD44v, 41, and proMMP-9 (or
MMP-9 since the Ab did not distinguish between the pro and
activated forms) colocalized at the B-CLL cell surface, we
performed immunofluorescence analyses using confocal micros-
copy and focused on cells with higher expression of MMP-9 for
easier visualization. As observed in Figure 6 for a representative
sample, the 4 or 1 subunits, as well as CD44v, colocalized with
MMP-9 (pro and/or activated) at the cell periphery, as documented
by dot-plot analysis. In contrast, CD44H, which did not coimmuno-
precipitate with proMMP-9 (Figure 1B) or 41 (Figure 5A), did
not colocalize with MMP-9 (Figure 6), confirming the specific
interaction of this MMP with CD44v.
We also analyzed by immunofluorescence the expression of
MMP-9 on B-CLL cells transfected with CD44, 1, or control
siRNAs. Figure S9 shows that knocking down the expression of
41 with 1 siRNA completely blocked MMP-9 localization
at the B-CLL cell surface, while CD44 expression was not
disturbed. Likewise, CD44 gene silencing resulted in the
complete loss of surface-associated MMP-9, while the expres-
sion of the 4 or 1 subunits was not affected. Transfection with
a control siRNA did not affect cell surface–bound MMP-9,
which colocalized with the 4 and 1 subunits but not with the
CD44H isoform (Figure S9).
Binding of proMMP-9 to the cell surface inhibits B-CLL cell
invasion through basement membranes and transendothelial
migration
We previously showed6 and have confirmed here (Figure 7A,B)
that gene silencing or Ab blocking endogenous MMP-9 inhibits
B-CLL cell migration and invasion. To determine whether binding
of exogenous proMMP-9 to B-CLL cells had a functional role in
these processes, we incubated B-CLL cells with various concentra-
tions of proMMP-9 and measured the migration through Matrigel
or HUVECs. Interestingly, a dose-response inhibition of cell
migration was observed in both systems (Figure S10A,B). This was
not due to a possible toxic effect of proMMP-9 since B-CLL cell
viability was not affected in these experiments (shown in Figure
S10C for 2 representative samples).
We next studied whether the proMMP-9 functional effect
involved binding to 41 and CD44. In the absence of exogenous
proMMP-9, Ab blocking or gene silencing 41 significantly
abolished B-CLL cell migration through Matrigel or HUVECs in
all samples studied (Figure 7A,B), confirming previous results.3,6
In contrast, inhibiting CD44 did not affect cell migration (Figure
7A,B). Adding proMMP-9 to cells with blocked 41 function or
expression resulted in inhibition of cell migration, probably due to
the effect of 41 itself (Figure 7A,B). However, exogenous
proMMP-9 was unable to inhibit migration on cells with blocked
CD44 expression or function (Figure 7A,B). These results con-
firmed that proMMP-9 effect on cell migration required the
interaction with its specific receptors (CD44 in this case).
To determine whether the inhibitory effect involved the enzy-
matic activity of MMP-9, we preincubated proMMP-9 with its
specific inhibitor TIMP-1 and measured the effect of the complex
on B-CLL cell migration. Efficient formation of the proMMP-9/
TIMP-1 complex was confirmed by immunoprecipitation with
anti–TIMP-1 Abs and subsequent analysis by gelatin zymography
(Figure 7C). Moreover, this complex bound equally well to B-CLL
cells as proMMP-9 alone (Figure 7D). B-CLL cell migration
through Matrigel (Figure 7E) or HUVECs (Figure 7F) was
significantly inhibited in all samples analyzed by TIMP-1 (average:
76% and 79% inhibition, respectively) or proMMP-9 (average:
93% and 91% inhibition, respectively). This effect was reverted in
both systems by cell incubation with the proMMP-9/TIMP-1
complex (Figure 7E,F). To confirm these results, we tested the
effect of the rproMMP-9mutE, which lacks enzymatic activity but
binds well to B-CLL cells (Figure 4B,C). Indeed, this mutant had
no effect on cell migration, while the parental rproMMP-9fl was as
effective as neutrophil-derived proMMP-9 (Figure 7E,F). As
expected, the rproMMP-9HemOG variant, which does not bind to
B-CLL cells, had no effect on cell migration (Figure 7E,F). These
results clearly established that surface-bound MMP-9 may regulate
B-CLL cell migration and this requires its proteolytic activity.
Figure 6. Colocalization of MMP-9 with CD44v and 41 integrin in B-CLL cells.
B-CLL cells from a representative sample were added to glass coverslips coated with
5 g/mL poly-lysine. After 1 hour at 37°C, cells were fixed and analyzed by confocal
microscopy using specific Abs for 4, 1, CD44v7,8, and CD44, followed by
Texas-Red–labeled secondary Abs. MMP-9 was detected with specific pAbs and
Alexa 488–labeled secondary Abs. Colocalization of MMP-9 with CD44v and 41
was further demonstrated using dot-plot analyses. Images were acquired using a
confocal scanning inverted AOBS/SP2 microscope (Leica Microsystems, Heidelberg,
Germany) with a 63/1.3 NA PL-APO glycerol immersion objective. Leica’s LCS
15.37 dye-separation software was used for colocalization studies; when necessary,
Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA) was used for image
processing. Bar represents 4 m.
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Discussion
We have studied the molecular associations and possible function
of MMP-9 at the B-CLL cell surface. We show for the first time that
(1) B-CLL cells bind soluble proMMP-9 and active MMP-9 and
attach to immobilized proMMP-9 and active MMP-9; (2) these
interactions are mediated by 41 integrin, 190-kDa CD44v, and
the MMP-9 hemopexin domain; (3) 41 and CD44v constitute a
novel cell surface docking complex for MMP-9; (4) MMP-9
colocalizes at the cell surface with 41 and CD44v, but not with
CD44H; and (5) surface-bound MMP-9 may regulate B-CLL cell
arrest and movement.
MMP-9 has previously been shown to interact with L2,
M2, V3, and V5 integrins on various normal and tumor
cell types.33,34 We show in the present study that 41 integrin is a
novel docking receptor for proMMP-9 and active MMP-9 in
B-CLL cells. Since 41 up-regulates proMMP-9,6 and this MMP
was shown to be involved in B-CLL cell movement,6,11 41 may
constitute a crucial player in the progression of this malignancy.
Indeed, elevated expression of 41 correlates with the presence of
lymphadenopathy,3 and 41 is required for chemokine-directed
B-CLL cell transendothelial migration.3,5 Moreover, the correlated
overexpression of the 4 integrin subunit and CD38 appears to be
characteristic of bad B-CLL prognosis.35,36 Our present results
support these findings and establish a novel function for 41 in
B-CLL (ie, anchoring MMP-9).
Our study also shows that the hyaluronan receptor CD4437,38 is
another specific receptor for proMMP-9 and active MMP-9 in
B-CLL cells. CD44 was previously shown to anchor MMP-9 at the
surface of human melanoma cells, and this involved both the
standard CD44H form as well as some CD44v isoforms.15 In
contrast with this study, proMMP-9 in B-CLL cells specifically
interacted and colocalized with a 190-kDa CD44v isoform but not
with CD44H, which is highly abundant in these cells. As mentioned
for 41, overexpression of cellular CD44v,39 in B-CLL or
presence of this form in serum,40,41 correlates with a more
aggressive disease and bad prognosis. This suggests that CD44v,
like 41, may also play a role in B-CLL progression. As we show
in the present study, one of the CD44v functions is to contribute to
and apparently be a determinant of proMMP-9 binding to B-CLL
cells. B cells lacking CD44v were unable to bind proMMP-9, albeit
expressing fully functional 41 integrin. In addition, our results
clearly show that 41 integrin and CD44v interact at the B-CLL
cell surface, indicating that they constitute a docking complex in
which both components are necessary for proMMP-9 surface
binding. This complex appears to function only when cell associ-
ated as, in results not shown, we did not observe proMMP-9
binding to isolated CD44v, 41 integrin, or both proteins
together, using solid-phase binding assays. One possible explana-
tion for this could be that the docking complex contains another
component(s), not yet identified, that regulates binding of
proMMP-9, or serves to bridge 41, CD44v, and proMMP-9.
Such bridging, or/and regulatory function for MMP-9 cell surface
binding, has already been described for dentin42 and osteopontin43
in colon and prostate cancer cells, respectively. While these issues
deserve further study, the present report is the first to show a
Figure 7. Functional effect of proMMP-9 binding on B-CLL cell migration through Matrigel and HUVECs. B-CLL cells (5  105), treated or not with the indicated Abs or
transfected with the indicated siRNAs, were incubated for 30 minutes with or without 10 g/mL proMMP-9. Cells were added to the upper chamber of Transwell filters coated
with either Matrigel (A) or TNF-–activated HUVECs (B), and 150 ng/mL CXCL12 was added to the medium in the bottom chamber. After 24 hours, migrated cells were counted
by flow cytometry. Average values (n 	 3) represent the percentage of the total number of cells added. (C) proMMP-9 was incubated in solution with TIMP-1 (110 nM each) for
30 minutes and the complex immunoprecipitated with anti–TIMP-1 or anti-HLA (Ctl) mAbs and protein G beads. Immunoprecipitates and supernatants were analyzed by
gelatin zymography. (D) B-CLL cells from a representative sample were incubated for 30 minutes with proMMP-9 alone or complexed to TIMP-1, and analyzed by flow
cytometry using anti–MMP-9 pAbs. Numbers indicate MFI values for basal MMP-9 (shaded areas) or exogenously added proMMP-9 or proMMP-9/TIMP-1 (continuous lines).
(E,F) B-CLL cells (5  105) were preincubated with or without the indicated proteins for 30 minutes at 4°C. Cells were washed and added to Transwell filters coated with
Matrigel (E) or TNF-–activated HUVECs (F), and migration was determined after 24 hours by flow cytometry. Average values (n 	 3) are expressed as the percentage of the
total number of cells added. T-1/pMMP-9 indicates TIMP-1/proMMP-9 complex. *P  .05; **P  .01.
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specific and apparently exclusive interaction between 41 inte-
grin and CD44v and a functional role for this complex.
Using recombinant proMMP-9 variants, we have demonstrated
that proMMP-9 interaction with this docking complex involves
mainly the hemopexin domain. 41 integrin and CD44v are
therefore novel ligands for this domain. In several cell types,
including B-CLL cells,6 cell-associated MMP-9 is found in
membrane-linked cytoskeletal superstructures for tissue inva-
sion,8,9,14,34 suggesting that MMP-9 targeting to the cell membrane
(via the hemopexin domain) may be a mechanism of controlling
tumor progression. In the present report, we have studied the
possible functional role of surface-bound proMMP-9 on B-CLL
cell migration. Although we previously showed,6 and confirmed
here, that endogenous MMP-9 appears to be required for B-CLL
movement, binding of exogenous proMMP-9 to B-CLL cells
clearly impaired directed cell migration in a chemotactic gradient.
The proteolytic activity of MMP-9 was necessary for this effect, as
established from the results with a TIMP-1/proMMP-9 complex
and an inactive recombinant proMMP-9 mutant, which did not
affect cell migration. As proMMP-9 represents the inactive en-
zyme, our findings strongly suggest that interaction of its he-
mopexin domain with 41 and CD44v results in activation of
proMMP-9 at the cell surface.
The mechanism involved in the observed functional effect is
currently unknown. Given the diversity of MMP-9 targets,7,44 it is
possible that when present at certain concentrations, surface-bound
MMP-9 cleaves substrates that are necessary for B-CLL cell
migration or/and induces cell adhesion. Opposite functional effects
according to the levels of MMP-9 expression have also been
observed in other tumor cell systems.45-48 It is therefore conceiv-
able that B-CLL cells that have migrated to the bone marrow or
lymph nodes increase their MMP-9 production, due to the action of
chemokines.6 Indeed, immunohistochemical studies have demon-
strated that B-CLL cells showing a diffused tissue infiltration
pattern (bad prognosis) express high levels of MMP-9.11 MMP-9
from other sources may also be present on these tissues and
facilitate B-CLL cell adhesion and arrest, rather than migration,
producing the observed accumulation of malignant cells typical of
B-CLL progression. The fact that the chemokine CXCL12 is a
substrate of MMP-9 might also be relevant in B-CLL biology.
Indeed, amino-terminal clipping of 4 residues of CXCL12 inacti-
vates the molecule49 and might destroy the chemotactic gradient in
the bone marrow. Because CXCL12 is a major chemoattractant for
CXCR4-positive cells, B-CLL clones that have reached the bone
marrow might become arrested and resident. The combination of
the MMP-9 proteolytic activity and its ability to mediate cell arrest
may therefore be crucial for B-CLL cell extravasation and localiza-
tion in tissues.
In summary, the present report is the first to identify 41
integrin and CD44v as a cell surface docking molecular complex
for proMMP-9 and active MMP-9. Our results can explain the
observed B-CLL cell–associated proMMP-9 and provide evidence
for a functional role of this MMP in the regulation of cell arrest and
movement in B-CLL. Understanding the regulation and function of
molecules involved in these processes is crucial for future therapies
aimed to prevent B-CLL progression.
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